Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 240,400 shares, a growth of 450.1% from the December 31st total of 43,700 shares. Approximately 2.9% of the shares of the company are short sold. Based on an average trading volume of 2,980,000 shares, the short-interest ratio is presently 0.1 days.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB traded up $0.43 on Tuesday, hitting $4.24. 613,538 shares of the company were exchanged, compared to its average volume of 493,136. Revelation Biosciences has a one year low of $3.61 and a one year high of $404.16. The firm has a market capitalization of $18.19 million, a price-to-earnings ratio of -0.25 and a beta of 0.24. The company’s 50 day moving average price is $0.56 and its two-hundred day moving average price is $0.87.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.